MAPT and amyloidosis: Monitoring CSF biomarkers such as Aβ42/Aβ40 and p-tau181 enables early identification of MBI, facilitating timely interventions that may include biomarker-guided screening, targeted therapies for amyloid/tau pathology, and lifestyle modifications to modulate neuroplasticity.